Masahiro Okada MD, Presenter: Nothing to Disclose

Yuko Iraha, Abstract Co-Author: Nothing to Disclose

KIMEI AZAMA, Abstract Co-Author: Nothing to Disclose

Kazushi Numata, Abstract Co-Author: Nothing to Disclose

Tomomi Koga, Abstract Co-Author: Nothing to Disclose

Sadayuki Murayama MD, PhD, Abstract Co-Author: Nothing to Disclose

1. To know the therapies for HCC, such as radio-frequency ablation (RFA), transcatheter arterial chemoembolization (TACE) and molecular targeted drug (Sorafenib). 2. To review typical and atypical findings of HCC on CT, US and MRI. 3. To know guidelines of response evaluation after HCC therapy 4. To define diagnostic accuracy and difficulty for HCC recurrence after therapy on CT, US and MRI. 5. To define diagnostic solution of HCC diagnosis after therapy. 6. To know potential pitfalls and limitations of contrast enhanced CT, US and MRI in the diagnosis of HCC.  

1 Morphology of HCC 2 Selection of HCC therapy • RFA • TACE • Molecular targeted drug (Sorafenib) 3 Classification of HCC • Borderline lesion • Early HCC • Advanced HCC 4 Modality of reccurence diagnosis of HCC ・　Dynamic CT and CT perfusion ・　Contrast-enhanced US ・　EOB-MRI and SPIO-MRI 5 Guidelines of response evaluation ・　Modified Response Evaluation Criteria in Solid Tumors　(RECIST) ・　Response Evaluation Criteria in Cancer of the Liver (RECICL) 6 Complication of HCC therapy 7 Potential pitfalls and limitations on CT, US and MRI after therapy of HCC  

http://abstract.rsna.org/uploads/2014/14006914/14006914_ot8c.pdf

Okada, M, Iraha, Y, AZAMA, K, Numata, K, Koga, T, Murayama, S, Hepatocellular Carcinoma: The Evaluation after Therapy by Advanced Imaging Tools.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14006914.html